DRILLAPP JavaScript backdoor targets Ukraine in Feb 2026, abusing Edge debugging features to spy via camera, microphone, and ...
The campaign, observed in February 2026, has been assessed to share overlaps with a prior campaign mounted by Laundry Bear, a ...
VectorCertain Analyzed 3,434 OpenClaw Pull Requests Using Multi-Model Consensus, Identified Systemic Governance Failures, and ...
Recursion Pharmaceuticals reports fourth-quarter and full-year 2025 results Wednesday before the market opens, with investors scrutinizing whether the AI-driven biotech can translate its massive data ...
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Recursion Pharmaceuticals (RXRX) closed at $3.42 in the latest trading session, marking a -8.06% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.69%.
Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results